Yahoo

ESMO 2025: Hutchmed’s VEGF plus Innovent’s PD-1 inhibitor bolsters PFS in RCC

Add Yahoo as a preferred source to see more of our stories on Google. Hutchmed's fruquintinib and Eli Lilly & Innovent Biologics' Tyvyt (sintilimab) significantly improved PFS during a Phase III trial ...
ascopubs.org

PD-1 inhibitor (sintilimab) and fruquintinib plus SOX as conversion therapy for initially unresectable gastric/gastroesophageal junction adenocarcinoma (GC/GEJC): Updated ...

Investigation of synergistic effects in trials of combination therapies with immune-checkpoint inhibitors in advanced gastric or gastroesophageal junction cancer. This is an ASCO Meeting Abstract from ...
ascopubs.org

Fruquintinib plus camrelizumab combined with paclitaxel liposome and nedaplatin as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm ...

Preliminary results of benmelstobart plus anlotinib combined with SOX in the first-line treatment of advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma with low PD-L1 expression: A ...